The deal, which is expected to be in the range of ₹100 crore, will enable SRF to expand and complement its existing offerings ...
KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α ...
KPL-387 is an independently developed monoclonal ... potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results